Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00139906 · ClinicalTrials.gov registry record · Phase 2
Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia
A Phase 2 study, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00139906: Completed Phase 2 study, sponsored by Solvay Pharmaceuticals.
NCT00139906 is a Phase 2 study that has completed, run by Solvay Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00139906, a Phase 2 study, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
This study is to assess the safety and tolerability of a five-day titration schedule (using twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg daily. The study duration is two months.
Interventions
- DRUG Bifeprunox
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-08 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
What the finished NCT00139906 record still lists
NCT00139906 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Bifeprunox is the first listed.
NCT00139906 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00139906 about?
NCT00139906 is a clinical study titled "Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia". This study is to assess the safety and tolerability of a five-day titration schedule (using twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg daily. The study duration is two months.
What is the current status of trial NCT00139906?
This trial is currently completed. It is a Phase 2 study. The study started on 2005-08. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00139906?
The interventions under investigation include: Bifeprunox (DRUG).
Who is sponsoring clinical trial NCT00139906?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia